This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks.com featured highlights include Transportadora de Gas del Sur, Lamb Weston, Vipshop and Novo Nordisk
by Zacks Equity Research
Transportadora de Gas del Sur, Lamb Weston, Vipshop and Novo Nordisk are part of the Zacks Screen of the Week article.
Novo Nordisk (NVO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Novo Nordisk (NVO) closed the most recent trading day at $165.37, moving +0.21% from the previous trading session.
Top Research Reports for Novo Nordisk, Salesforce & Comcast
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Salesforce, Inc. (CRM) and Comcast Corporation (CMCSA).
Roche (RHHBY) Polivy Combination for DLBCL Gets Full Approval
by Zacks Equity Research
Roche (RHHBY) gets full approval for Polivy (polatuzumab vedotin-piiq) in combination with Rituxan, cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of adult patients who have previously untreated DLBCL.
Are Medical Stocks Lagging Novo Nordisk (NVO) This Year?
by Zacks Equity Research
Here is how Novo Nordisk (NVO) and Novartis (NVS) have performed compared to their sector so far this year.
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
by Zacks Equity Research
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Will Sanofi (SNY) Surpass Estimates This Earnings Season?
by Zacks Equity Research
Sanofi's (SNY) top line is likely to have been driven by higher sales of Dupixent.
Buy These 4 Low-Beta Stocks to Sail Through Market Volatility
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Transportadora de Gas (TGS), Lamb Weston (LW), Vipshop (VIPS) and Novo Nordisk (NVO) are well-poised to gain.
Biogen (BIIB) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of multiple sclerosis drugs, while sales of Spinraza are likely to have improved.
Vaxcyte (PCVX) Up on Pneumococcal Conjugate Vaccine Data
by Zacks Equity Research
Vaxcyte (PCVX) announces positive results from the mid-stage study of its 24-Valent pneumococcal conjugate vaccine candidate, VAX-24, in adults aged 65 and older.
Nektar (NKTR) Starts New Restructuring Plan to Curb Cash Burn
by Zacks Equity Research
The new restructuring plan will allow Nektar (NKTR) to extend its cash runway into mid-2026. The company plans to reduce its workforce by approximately 60%.
FDA Expands AbbVie's (ABBV) Qulipta Label in Chronic Migraine
by Zacks Equity Research
Following FDA's label-expansion approval, AbbVie's (ABBV) Qulipta is the first and the only oral CGRP receptor antagonist approved to prevent episodic and chronic migraines.
J&J (JNJ) Q1 Earnings & Sales Top, 2023 View Up, Stock Rises
by Zacks Equity Research
J&J (JNJ) beats estimates for first-quarter earnings and sales. It raises full-year sales and earnings guidance.
Bristol Myers (BMY), TSVT Application for Abecma Accepted
by Zacks Equity Research
Bristol Myers (BMY) and partner TSVTs sBLA for CAR T cell therapy is accepted by the FDA for earlier lines of treatment in multiple myeloma.
Roche (RHHBY) Announces Data on Tecentriq Combo for HCC
by Zacks Equity Research
Roche's (RHHBY) new data from the late-stage IMbrave050 study reveals that the combination of Tecentriq and Avastin reduces the risk of cancer relapsing in people with certain types of adjuvant liver cancer in a phase III study.
Will J&J (JNJ) Pharma Unit Outperform Market & Drive Q1 Results?
by Zacks Equity Research
In J&J's (JNJ) Pharma segment, its oncology drug, Darzalex as well as a psoriasis treatment, Stelara is likely to have driven sales growth in the first quarter
Prometheus (RXDX) Stock Surges 70% on Buyout Offer From Merck
by Zacks Equity Research
Prometheus (RXDX) is set to be acquired by Merck for $11 billion, adding Prometheus' lead product candidate, PRA023, to Merck's portfolio. Prometheus' stock is up 70%.
Novo Nordisk (NVO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Novo Nordisk (NVO) closed at $168.60, marking a +0.57% move from the previous day.
Amylyx (AMLX) Doses First Patient in Wolfram Syndrome Study
by Zacks Equity Research
Amylyx (AMLX) progresses with the phase II study of pipeline candidate AMX0035 for the treatment of Wolfram syndrome as it doses the first patient.
Merck's (MRK) Keytruda sBLA Accepted by FDA for Gastric Cancer
by Zacks Equity Research
Merck's (MRK) application seeking approval for Keytruda in combination with fluoropyrimidine- and platinum-containing chemotherapy for the early treatment of locally advanced, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma was accepted by the FDA.
Sarepta Down on Reports of FDA Almost Rejecting DMD Gene Therapy
by Zacks Equity Research
Per a Stat News article, the FDA initially considered rejecting Sarepta's (SRPT) regulatory filing seeking FDA's accelerated approval for DMD gene therapy.
Are You Looking for a Top Momentum Pick? Why Novo Nordisk (NVO) is a Great Choice
by Zacks Equity Research
Does Novo Nordisk (NVO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Lilly's (LLY) Ulcerative Colitis Candidate Gets CRL from FDA
by Zacks Equity Research
The FDA rejects Eli Lilly's (LLY) regulatory filing seeking approval for mirikizumab to treat ulcerative colitis indication, citing issues related to the drug's proposed manufacturing.
Novo Nordisk (NVO) Increases Sales & Operating Profit Guidance
by Zacks Equity Research
Novo Nordisk (NVO) increases annual guidance for the year 2023 on higher sales expectations for Ozempic and Wegovy.
J&J (JNJ) to Initiate Q1 Earnings Season for Pharma Sector
by Zacks Equity Research
Growth in J&J's (JNJ) Pharma unit is expected to have been driven by drugs like Darzalex and Stelara. In the MedTech segment, continued recovery in worldwide procedure volume should drive sales.